Henry Gosebruch

Chief Strategy Officer
Abbvie

Henry Gosebruch is Executive Vice President and Chief Strategy Officer at AbbVie, a global biopharmaceutical company with a current market capitalization of approximately $250 billion and revenues of more than $50 billion. As a member of AbbVie’s Executive Leadership Team, he is responsible for Corporate Strategy, Business Development & Acquisitions, Search & Evaluation, Alliance Management, R&D decision support/portfolio analytics and AbbVie Ventures. Henry and his team have completed over 100 business development/M&A transactions and venture capital investments since 2015. His organization consists of approximately 80 colleagues globally.

Prior to his AbbVie appointment in late 2015, Henry was Co-Head of J.P. Morgan’s North American M&A Group based in New York. He was a member of J.P. Morgan’s M&A group for more than 20 years where he worked on announced M&A transactions in excess of $375 billion in total value involving companies in more than 20 countries.

Henry is a German citizen and fluent in German. He graduated magna cum laude from the Wharton School at the University of Pennsylvania in 1995 with a BSE. Henry is a member of the board of directors at Aptinyx (NASDAQ: APTX) where he serves on the audit and compensation committees and the advisory board of the Life Sciences & Management Program at the University of Pennsylvania. He is a licensed CPA in Illinois and graduate of G100 Next Gen. Henry and his wife have three boys and live in Chicago.